Navigation Links
TorreyPines Therapeutics Reports First Quarter 2009 Financial Results
Date:5/1/2009

$4,878 $5,305 Long-term debt, net of current portion - 2,112 Total liabilities 4,878 7,417 Total stockholders' equity 1,831 3,713 Total liabilities and stockholders' equity $6,709 $11,130

                          TorreyPines Therapeutics, Inc.
                Condensed Consolidated Statements of Operations

                   (in thousands, except per share amounts)
                                (Unaudited)

                                                     Three months ended
                                                          March 31,
                                                      2009         2008

    Revenue                                             $-       $2,046

    Operating expenses:
      Research and development                         855        5,260
      General and administrative                     1,268        1,448
    Total operating expenses                         2,123        6,708

    Loss from operations                            (2,123)      (4,662)

    Other income (expense)
      Interest income                                    8          217
      Interest expense                                 (45)        (147)
      Other income (expense), net                       40          699
    Total other income                                   3          769

    Net loss                                       $(2,120)     $(3,893)

    Basic and diluted net loss per share            $(0.13)      $(0.25)

    Weighted average shares used in the
     computation of basic and diluted net
     loss per share                             15,974,058   15,739,646

    Company Contact:
    Craig Johnson
    TorreyPines Therapeutics, Inc.
    858-623-5665, x158
    '/>"/>
SOURCE TorreyPines Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. TorreyPines Therapeutics to Present at the NewsMakers in the Biotech Industry Conference
2. TorreyPines Therapeutics to Present at ThinkEquitys G5 Conference
3. TorreyPines Therapeutics and Eisai Co., Ltd. Extend Genetics Discovery Collaboration for Alzheimers Disease
4. TorreyPines Therapeutics to Present at ThinkEquitys ThinkClinic Conference
5. TorreyPines Therapeutics to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
6. TorreyPines Therapeutics Reports Third Quarter 2007 Results
7. TorreyPines Therapeutics to Present at Susquehanna Financial Groups Second Annual SIGnificant Options in Healthcare Conference
8. TorreyPines Therapeutics Initiates Phase II Study of Muscarinic Agonist NGX267 for Treatment of Xerostomia
9. TorreyPines Therapeutics Reports Fourth Quarter and Full Year 2007 Financial Results and Highlights
10. TorreyPines Therapeutics to Host First Quarter 2008 Results Conference Call and Webcast
11. TorreyPines Therapeutics to Present Tezampanel Phase IIb Clinical Data for Acute Migraine at 50th Annual Scientific Meeting of the American Headache Society
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... August 19, 2014 Sales Horizons, a ... its online sales skills training course to ... , MedTech clinical staff spend the majority of their ... standalone medical center, or physician practice – providing support ... why stop there? Sales Horizons believes clinical staff are ...
(Date:8/18/2014)... FREDERICK, Md. , Aug. 18, 2014 ... the maker of advanced consumer medical devices ... Kotak was interviewed by CEOLIVE.TV as ... The entire interview is available at ... interview Dr. Kotak explains to investors the ...
(Date:8/18/2014)... 18, 2014 According to ... Research "Life Science Reagents Market(Products- PCR Reagent Kits, ... In-Vitro Diagnostic Reagents and Others; End Users- Commercial ... Laboratories, and Forensic Laboratories)- Global Industry Analysis, Size, ... the global life science reagents market was valued ...
(Date:8/18/2014)... China is increasingly being recognized ... research industry. Clinicaltrial.gov statistics highlight the popularity of ... population; a high increase in infectious diseases; a ... pool of patients and a track record of ... China also presents challenges for the clinical research ...
Breaking Biology Technology:Sales Horizons Launches a New Online Sales Training Course for MedTech Clinical Staff to Develop Their Sales Skills 2Sales Horizons Launches a New Online Sales Training Course for MedTech Clinical Staff to Develop Their Sales Skills 3BioElectronics EVP Dr. Deepak Kotak Interviewed on CEO Live 2BioElectronics EVP Dr. Deepak Kotak Interviewed on CEO Live 3Global Life Science Reagents Market Expected to Reach USD 25.7 Billion in 2019: Transparency Market Research 2Global Life Science Reagents Market Expected to Reach USD 25.7 Billion in 2019: Transparency Market Research 3Global Life Science Reagents Market Expected to Reach USD 25.7 Billion in 2019: Transparency Market Research 4Global Life Science Reagents Market Expected to Reach USD 25.7 Billion in 2019: Transparency Market Research 5China – Land of Opportunities & Challenges for the Clinical Research Industry, New Webinar Hosted by Xtalks 2
... March 20 On Wednesday, April 29, 2009, Wyeth (NYSE: ... 2009 first quarter. The Company will hold a forty-five minute ... on April 29, 2009. Interested investors and others may ... through our Internet webcast, which may be accessed by visiting ...
... Solos Endoscopy, Inc. (Pink Sheets: SNDY) is pleased ... agreement with Lifeline Biotechnologies, Inc. (Pink Sheets: LLBO) ... to Lifeline Biotechnologies for a combination of stock, ... Endoscopy originally purchased the products from Lifeline Biotechnologies ...
... has shown that certain marginalized groups including the ... African Americans and Latinos fare worse than others ... injuries and fatalities. , Now, a ... that they also experience greater terrorism-related fears and make ...
Cached Biology Technology:Wyeth Sets Webcast and Conference Call for 2009 First Quarter Earnings 2Solos Endoscopy, Inc. Sells Ovascope and Mastascope Product Line to Lifeline Biotechnologies, Inc. 2Disabled and other vulnerable groups more susceptible to terrorism fears 2
(Date:8/19/2014)... It,s not a monkey. It,s not a lemur. It,s ... Meet the Philippine tarsier: a tiny, adorable and downright "cool" ... animals that Americans are familiar with," said Rafe Brown, curator-in-charge ... giant eyes and ears; an extremely cute, furry body; a ... interesting expanded fingers and toe tips that look a bit ...
(Date:8/19/2014)... a new implantable tissue scaffold coated with bone growth ... When applied to bone injuries or defects, this coated ... that looks and behaves just like the original tissue. ... dramatic improvement over the current standard for treating bone ... the patient,s body a painful process that does ...
(Date:8/19/2014)... ( Aug. 19, 2014 ) -- Scientists at the ... pick up and transfer single cells using a pipette ... They describe this engineering feat and preliminary test results ... the American Chemical Society . , "Studying single cells ... current biomedical research," said nanomedicine department. faculty member Lidong ...
Breaking Biology News(10 mins):Philippine tarsier gets boost from Kansas research, and genetic proof of a new variety 2Philippine tarsier gets boost from Kansas research, and genetic proof of a new variety 3Engineering new bone growth 2Engineering new bone growth 3Moving single cells around -- accurately and cheaply 2
... NY-- A multinational team of scientists has identified a single gene, ... fruit and seeds of the oil palm are the source of ... provide one of the most promising sources of biofuel. ... high-quality full genome map of the oil palm plant and to ...
... in California,s Central Valley, one of the world,s most ... species miles from farmland. Writing in Environmental Toxicology ... Tree Fogs in remote mountain areas, including national parks; ... by the elements. California,s Central Valley is one ...
... The following statement is being issued by Robbins Geller Rudman & Dowd ... Litigation SUPERIOR COURT OF THE STATE OF CALIFORNIA ... IN RE PACIFIC BIOSCIENCES OF CALIFORNIA , INC. SECURITIES ... OF PROPOSED SETTLEMENT OF CLASS ACTION Hon. Marie S. Weiner ...
Cached Biology News:Full genome map of oil palm indicates a way to raise yields and protect rainforest 2Full genome map of oil palm indicates a way to raise yields and protect rainforest 3Pesticides contaminate frogs from Californian National Parks 2Robbins Geller Rudman & Dowd LLP and Scott+Scott, Attorneys at Law, LLP Announce Proposed Settlement of Class Action in the Pacific Biosciences Securities Litigation 2Robbins Geller Rudman & Dowd LLP and Scott+Scott, Attorneys at Law, LLP Announce Proposed Settlement of Class Action in the Pacific Biosciences Securities Litigation 3Robbins Geller Rudman & Dowd LLP and Scott+Scott, Attorneys at Law, LLP Announce Proposed Settlement of Class Action in the Pacific Biosciences Securities Litigation 4
Negative Control, eluted and packaged aseptically in 20l of 10mM Tris-HCL, pH 8.0, 1 mM EDTA, 5 years at either 4°C or -20°C...
AdestaTM Tissue/Cell Preservation Medium Sterile / Non-sterile: Sterility Tested Endotoxin: ...
...
... Clone/PAD: ZMD.440. Immunogen: Synthetic peptide derived ... PDGF-D (platelet derived growth factor D iris-expressed ... which differs from mouse and rat by ... with the ~50 kDa human mouse and ...
Biology Products: